Structure-based drug discovery also bears a great potential in the low-data setting . These approaches, in fact, can leverage large corpora of protein-ligand affinity annotations, and can apply them to targets for which little (or no) ligand affinity information is available. Current structure-based approaches do not necessarily outperform approaches based on ligand information only , and hence we encourage the cheminformatics community to explore novel strategies to combine protein structure and ligand information with deep learning. Finally, multimodal learning , , and meta-learning , , strategies are getting increasing traction, and we expect them to become commonplace in drug discovery with low-data.